The increase in price target by Stifel reflects a positive outlook on Syndax Pharmaceuticals, likely due to the company's strong fundamentals or potential upcoming positive developments. This endorsement from a reputable analyst could lead to increased investor confidence and a potential short-term uptick in SNDX's stock price.